DAE HWA Pharmaceutical Co., Ltd.

A067080

KR7067080002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/05/2024 BST			5-day change	1st Jan Change
10,210 ^KRW	+1.39%		-5.20%	+8.85%

2022	DAE HWA Pharmaceutical Co., Ltd.(KOSDAQ:A067080) dropped from S&P Global BMI Index	CI
2019	Mediforum Co.,Ltd. acquired 13.9% stake in C-TRI Co., Ltd. from DAE HWA Pharmaceutical Co., Ltd. and Wanjoo Kim for KRW 20.2 billion.	CI

DAE HWA Pharmaceutical Co., Ltd. announced that it has received KRW 20 billion in funding

March 28, 2019

On March 29, 2019, DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:A067080) closed the transaction.

Latest news about DAE HWA Pharmaceutical Co., Ltd.

DAE HWA Pharmaceutical Co., Ltd.(KOSDAQ:A067080) dropped from S&P Global BMI Index	19/09/22	CI
Mediforum Co.,Ltd. acquired 13.9% stake in C-TRI Co., Ltd. from DAE HWA Pharmaceutical Co., Ltd. and Wanjoo Kim for KRW 20.2 billion.	04/12/19	CI
DAE HWA Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 6, 2019, has expired.	05/11/19	CI
DAE HWA Pharmaceutical Co., Ltd. announces an Equity Buyback for 360,000 shares.	06/08/19	CI
DAE HWA Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	05/08/19	CI
DAE HWA Pharmaceutical Co., Ltd. announced that it has received KRW 20 billion in funding	28/03/19	CI
DAE HWA Pharmaceutical Co., Ltd. announced that it expects to receive KRW 20 billion in funding	27/03/19	CI
Shanghai Haihe Biopharma Co., Ltd. announced that it has received $146.6 million in funding from a group of investors	10/02/19	CI
DAE HWA Pharmaceutical Co., Ltd.(KOSDAQ:A067080) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	01/12/15	CI
DAE HWA Pharmaceutical Co., Ltd.(KOSDAQ:A067080) added to S&P Global BMI Index	21/09/15	CI
DAE HWA Pharmaceutical Co., Ltd.(KOSDAQ:A067080) added to Russell Global Index	29/06/15	CI
DAE HWA Pharmaceutical Co., Ltd. cancelled the acquisition of REDOXBIL CO.,LTD.	31/07/14	CI
DAE HWA Pharmaceutical Co., Ltd. agreed to acquire REDOXBIL CO.,LTD. for KRW 1.1 billion.	31/07/13	CI
Dae Hwa Pharmaceutical Co., Ltd Proposes Dividend	27/02/13	CI

Chart DAE HWA Pharmaceutical Co., Ltd.

Duration

Period

More charts

DAE HWA PHARM CO.,LTD. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include skeletal muscle relaxants, gastro-intestinal drugs, corticosteroids, antihistamines, cardiovascular drugs, drugs for liver diseases, vitamins, tonics, antibiotics, injections, topical drugs, anti-inflammatory enzymes, analgesics, antipyretics, plaster, cough suppressants, expectorants and mucolytics, drugs for hemorrhoid disease and other prescription drugs, as well as over-the-counter (OTC) drugs. The Company distributes its products within domestic market and to overseas markets. On August 22, 2013, it acquired a certain shares of a Korea-based company, which is mainly engaged in the manufacture of medicine raw materials and development of medical devices. After the transaction, the Company held a 100% stake of the Korea-based company.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
DAE HWA PHARMACEUTICAL CO., LTD.	+8.85%	131M
MERCK KGAA	+15.09%	74.45B
KYOWA KIRIN CO. LTD.	+11.35%	9.18B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.35%	5.03B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.02B
YUHAN CORPORATION	+1.60%	3.82B
BETTA PHARMACEUTICALS CO., LTD.	-20.85%	2.41B
INDIVIOR PLC	+16.88%	2.39B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.25%	2.27B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.26B

Specialty & Advanced Pharmaceuticals